Zevenbergen Capital Investments LLC Purchases 62,098 Shares of DexCom, Inc. $DXCM

Zevenbergen Capital Investments LLC lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 10.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 685,433 shares of the medical device company’s stock after buying an additional 62,098 shares during the period. Zevenbergen Capital Investments LLC owned about 0.17% of DexCom worth $46,123,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. SWS Partners bought a new position in shares of DexCom during the second quarter valued at about $1,661,000. Baader Bank Aktiengesellschaft purchased a new stake in DexCom during the 2nd quarter valued at about $393,000. Jennison Associates LLC grew its position in DexCom by 9.4% during the 2nd quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock worth $1,005,367,000 after acquiring an additional 994,300 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in DexCom by 85.7% in the second quarter. Assenagon Asset Management S.A. now owns 1,208,255 shares of the medical device company’s stock valued at $105,469,000 after purchasing an additional 557,576 shares during the last quarter. Finally, Mn Services Vermogensbeheer B.V. lifted its position in DexCom by 4.9% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 146,600 shares of the medical device company’s stock valued at $12,797,000 after purchasing an additional 6,800 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom News Summary

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Several broker notes and target raises lift sentiment: Canaccord Genuity initiated/maintained a Buy and Mizuho reiterated optimism (including a price-target raise to $78), while Robert W. Baird kept a Buy rating — these research calls support upside expectations for DXCM. Dexcom Gets a Buy from Canaccord Mizuho raises PT to $78 Baird keeps Buy
• Neutral Sentiment: Analyst coverage pieces (e.g., Mizuho / other note coverage) and retrospective pieces highlighting that DXCM has lost ~43% over three years give context to valuation and risk but don’t change near-term fundamentals by themselves. Investors lost 43% over 3 years Mizuho Forecasts Strong Price Appreciation
• Negative Sentiment: Multiple law firms have issued class-action notices and solicitations (Levi & Korsinsky, Schall Law, Gross Law, Halper Sadeh, Schall, Schall Law Firm), indicating potential securities litigation tied to alleged disclosures between 2024–2025; this creates legal overhang and downside risk for shareholders. Levi & Korsinsky class action notice Halper Sadeh notice Schall Law Firm notice Gross Law Firm reminder
• Negative Sentiment: Investor letters and analysis cite modest guidance as a driver of recent share weakness; lingering concerns on near-term growth/operating cadence could limit upside despite analyst optimism. Modest guidance cited as reason for fall

DexCom Trading Up 0.2%

DXCM opened at $66.05 on Friday. The company has a quick ratio of 1.38, a current ratio of 1.56 and a debt-to-equity ratio of 0.45. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $93.25. The stock has a market cap of $25.76 billion, a PE ratio of 36.69, a PEG ratio of 1.42 and a beta of 1.51. The business has a 50 day moving average of $63.94 and a 200-day moving average of $73.84.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.04. The company had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.18 billion. DexCom had a return on equity of 30.65% and a net margin of 15.96%.The firm’s revenue for the quarter was up 21.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.45 earnings per share. Equities research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently commented on DXCM shares. Citigroup reiterated a “buy” rating and set a $77.00 price target (up from $75.00) on shares of DexCom in a report on Thursday, December 11th. Robert W. Baird set a $82.00 target price on shares of DexCom in a report on Friday, October 31st. Morgan Stanley upgraded DexCom from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $63.00 to $75.00 in a report on Tuesday, December 2nd. Evercore ISI started coverage on DexCom in a report on Tuesday, November 25th. They issued an “in-line” rating and a $68.00 price objective for the company. Finally, JPMorgan Chase & Co. cut their price objective on DexCom from $90.00 to $75.00 and set a “neutral” rating on the stock in a research report on Friday, October 31st. Three research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and a consensus price target of $86.61.

Insider Buying and Selling

In related news, Director Bridgette P. Heller sold 1,012 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total value of $58,766.84. Following the sale, the director owned 27,031 shares in the company, valued at $1,569,690.17. This represents a 3.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Richard Alexander Collins sold 2,906 shares of the firm’s stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $59.05, for a total value of $171,599.30. Following the transaction, the director directly owned 35,088 shares of the company’s stock, valued at approximately $2,071,946.40. This trade represents a 7.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 7,866 shares of company stock valued at $448,177 over the last quarter. Corporate insiders own 0.32% of the company’s stock.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.